InvestorsHub Logo
Followers 28
Posts 6019
Boards Moderated 0
Alias Born 10/30/2013

Re: TheHungryHippo post# 11132

Thursday, 12/13/2018 9:46:54 AM

Thursday, December 13, 2018 9:46:54 AM

Post# of 27639
We are very satisfied with these new results because we now have a strong data base to expect successful clinical development of our second-generation COP Allergy Vaccines,” said Vincent Charlon, CEO of Anergis. “The new presentation of our peptides ensured a boost in immunogenicity without the development of specific IgEs during treatment. This combination should result in greater efficacy and improved tolerability as compared to the first generation. We will be happy to discuss the results in further detail at the upcoming Biotech Showcase / J.P. Morgan Healthcare Conference in San Francisco in January.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MYMX News